METHODS: A total of 98 consecutive patients(98 eyes)with CEC treated in our hospital from September 2013 to May 2015 were enrolled in this study and randomly divided into 2 groups. The experimental group received intravitreal injection of ranibizumab treatment, were treated with compound Xueshuantong capsule, 3 consecutive months of treatment; the control group only treated with compound Xueshuantong capsule treatment, the same dosage and course of treatment with the experimental group. Two groups of patients were reviewed monthly, the follow-up time was 6mo. Before and after treatment, visual acuity, foveal retinal thickness and leakage area were measured.

RESULTS: Visual acuity(LogMAR): the visual acuity of the two groups before and after surgery was significantly different(P<0.05); the visual acuity of the experimental group was significantly better than that of the control group, the difference was statistically significant(P<0.05). There was significant difference between experimental group and control group on central macular thickness macular(CMT)(P<0.05), which of experimental group decreased more than that of control group. The improved leakage of the two groups was significant different by χ2 test(P<0.05).

CONCLUSION: Ranibizumab combined with compound Xueshuantong capsule in the treatment of CEC can reduce vascular leakage, reduce macular edema, shorten the course, improve eyesight, which is a safe and effective method for the treatment of CEC. Multiple intravitreal injection of ranibizumab to CEC can improve the vision of patients and keep it stable.